• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22323 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec/liraglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec (addendum to commission A15-10)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Insulin degludec - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2015     The Swedish Council on Health Technology Assessment (SBU) [Instruments for suicide risk assessment]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inotuzumab ozogamicin (acute lymphocytic leukaemia) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inotersen (hereditary transthyretin amyloidosis with polyneuropathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Initial staging of oesophageal cancer: systematic review of the performance of diagnostic methods]
2009     Institute for Clinical Effectiveness and Health Policy (IECS) [Inhaled tobramycin for cystic fibrosis]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inhaled insulin (Exubera) in diabetes mellitus - rapid report]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Inhalation tobramycin for the management of cystic fibrosis]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Inguinal hernia: clinical practice guideline]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Inguinal hernia management: operation or observation? A randomised controlled multicenter trial]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Infrared meibography for meibomian gland disease]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Informative value of Patient-Reported Outcomes (PRO) in Health Technology Assessment (HTA)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Information, consent and medical counselling on ultrasound screening in pregnancy]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Information to users on cancer screening in women: assessment of current situation and establishment of evidence-based information standards. 1. Information to users on breast cancer screening]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Information to users on cancer screening in women: assessment of current situation and establishment of evidence-based information standards 2. Information to users on cervical cancer screening]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Information to parents about neonatal screening for inborn errors of metabolism: assessment of current situation and establishment evidence-based information standards]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Information resources: developing user guides]
2006     Basque Office for Health Technology Assessment (OSTEBA) [Information required for analyzing the impact of the early breast cancer detection programme]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Information for health insurance fund members on ultrasound screening for abdominal aortic aneurysms: addendum to commission S13-04]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Information for health insurance fund members on prenatal testing]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Information brief concerning palliative care day centres]
2009     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Information and communications technologies in mental health (Telepsychiatry)]
2009     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Information and communications technologies in CHF management programmes. Organizational challenges and evidence status]
2008     Committee for New Health Technology Assessment (CNHTA) [Influenza virus A & B, RT-nested PCR]
2021     Health Council of the Netherlands Gezondheidsraad (GR) [Influenza vaccination: review of indications]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Influenza vaccination of the elderly (funded by DIHTA)]
2022     Canary Health Service [Influenza vaccination in children 6 to 59 months of age]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Influence of an existing health care plan aimed at managing ST-elevation myocardial infarction on the waiting time until re-perfusion, and types of re-perfusion. Pilot study]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature]
2004     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Infliximab (REMICADE) in patients with rheumatoid arthritis; systematic review of the clinical and economic literature]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) - Benefit assessment according to § 35a SGB V]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Induction of labour versus expectant management in women with preterm premature rupture of membranes between 34 and 37 weeks (PPROMEXIL-study)]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Induction of labour at 41 completed until 42 completed gestational weeks, update of mini-HTA VGR 2007]
2019     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Induction immunosuppressive therapy in patients undergoing heart transplantation]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Induced sputum in severe asthma patients]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Individualised multidisciplinary care programme in frail patients (PAMI)]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Individual health services]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Indirect comparisons of therapeutic interventions]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [Indirect comparison methodology research for health technology assessment: Comparison of drug treatment effect in adult attention deficit hyperactivity disorder using a common comparator]
2019     Basque Office for Health Technology Assessment (OSTEBA) [Indications, utility and use of ultrasound in primary care]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Indications for positron emission tomography (pet): a brief update]
2008     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Indications for hyperbaric oxygen therapy: update]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Indications and recommendations for the use of PET-CT in the planning of radiation oncology treatment. Systematic review]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indicaterol/glycopyrronium - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2024     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Indicated prevention of suicide in children and adolescents]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Increase of physical activity in essential hypertension - Rapid report]
2023     Health Sciences Institute in Aragon (IACS) [Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2011     Andalusian Health Technology Assessment Area (AETSA) [Inclusion of new health technologies into Spanish hospitals]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Inclisiran (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Incidence of errors in intensive care: effects of increased awareness and of improved communication by the introduction of explicit daily goals]
2006     Basque Office for Health Technology Assessment (OSTEBA) [Incidence of diabetic retinopathy based on a screening programme using a non-mydriatic retinal camera on diabetic patients in the Autonomous Community of the Basque Country]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [In-toto thrombectomy using a retriever/aspiration system for acute pulmonary artery embolism - Addendum to commission H22-04]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [In vitro fertilization: comparative profile of European and Oceania countries]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Improving the efficiency and quality of follow-up after curative treatment for breast cancer]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Improving the early diagnosis of myocardial infarction in primary care: the added value of a rapid assay to detect heart-type FABP, a novel marker of cardiac injury]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Improving the care of elderly patients with chronic pathologies]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Improving lifestyle adherence in patients with high risk for cardiovascular diseases in general practice. Costs and effects of patient involvement in cardiovascular risk management]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementing a routine outcome monitoring system to study the effectiveness of long-term psychoanalytic treatment and therapeutic decision making in four cohorts of personality disordered and/ or recurrent or chronic depressive patients]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of the WIP guideline 'Prevention of infections due to urethral bladder catheterization']
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of structural feedback by means of perinatal audit to caregivers in cases of perinatal mortality in the northern part of the Netherlands (IMPACT)]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of selective karyotyping in couples with recurrent miscarriage]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of screening and treatment of high-risk fracture patients by an osteoporosis nurse-practitioner]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Implementation of quality indicators to assess the high risk of colorectal cancer clinic]
2012     The Swedish Council on Health Technology Assessment (SBU) [Implementation of psychiatric guidelines and evidence-based knowledge in the primary care sector]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of outpatient schema focused therapy for borderline personality disorder in three settings: general community mental health centers, forensic centers and addiction treatment centers]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of intensive insulin therapy (IIT) in critically ill patients, targeting at normoglycemia while preventing hypoglycemia]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implementation of guidelines - obstructive and beneficial factors]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of evidence-based guidelines for appropriate use of ultrasonography in diagnostic breast imaging: the MAMMOED-2 study]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of an evidence based smoking cessation strategy (SMOCC) for patients with COPD in primary care]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [IMPlementation of a prediction rule in Anesthesia practice to improve Cost-effectiveness of Treatment of postoperative nausea and vomiting: the IMPACT trial]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of a new cost-effective treatment (HIT) for patients with therapy refractory auditory hallucinations]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [Implementation of a multiple intervention aimed at optimising prescription of antibiotics for respiratory tract infections, embedded within the new practice accreditation of the Dutch College of General Practitioners; a randomized controlled trial]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Implementation and development of a treatment programme for peritoneal carcinomatosis in Catalonia. Indications and clinical results using Sugarbaker's technique]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2009     Committee for New Health Technology Assessment (CNHTA) [Implantation technology of autologous chondrocyte using fibrin]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a permanent embolic protection in patients with non-valvular attrial fibrillation in left auricular appendage]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Implantable ventricular assist devices: assessment of evidence and required elements to establish a clinical registry in Québec]
2022     Canary Health Service [Implantable neurostimulation device for the treatment of drug-resistant pediatric epilepsy]
2008     Committee for New Health Technology Assessment (CNHTA) [Implantable drug infusion pump implantation]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Implantable devices for left atrial appendage closure. Monitoring study]
1999     Andalusian Health Technology Assessment Area (AETSA) [Implantable defibrillators: criteria for clinical indications and decision making on coverage - non-systematic review]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac monitors in syncope of unknown etiology]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac defibrillator for primary prevention of sudden death]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable and programmable sacral neuromodulator (Interstim®) treatment of urinary, fecal and combined incontinence]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implant-supported supraconstructions for the treatment of shortened dental arches]
2011     Andalusian Health Technology Assessment Area (AETSA) [Impella Recover® 2.5 ventricular assist device]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of EFQM in Osakidetza]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]